期刊文献+

盐酸法舒地尔治疗不稳定型心绞痛的疗效和安全性 被引量:2

The curative effect and safety of fasudil hydrochloride in unstable angin
下载PDF
导出
摘要 目的 探讨盐酸法舒地尔治疗冠心病不稳定型心绞痛的疗效和安全性.方法 将70例患者分为治疗组和对照组,治疗组在常规治疗基础上予盐酸法舒地尔,观察两组治疗前后的临床疗效和心电图疗效,CRP、BNP值及其他临床状况.结果 治疗组症状和心电图总有效率为91.4%和85.7%,而对照组为71.4%和60.0%,两组比较差异有统计学意义(P〈0.05).治疗后治疗组心电图与对照组比较,各项指标均明显改善(P〈0.05),CPR和BNP值与对照组比较下降更明显(P〈0.05).治疗组心率、血压和肝肾功能、凝血指标在治疗前后比较差异无统计学意义(P〉0.05).结论 盐酸法舒地尔治疗不稳定型心绞痛有效安全,值得推广和进一步研究. Objective To investigate the curative effect and safety of fasudil hydrochloride used in unsta- ble angina. Methods 70 cases of unstable angina were divided into two groups which were the treatment group and the control group, the treatment group was treated by fasudil hydrochloride on the base of common treatment. The clinical efficacy of the two groups before and after treatment, including ECG curative effect, CRP, BNP value and other clinical conditions were observed. Results The total effective rate of symptom and ECG in treatment group was 91.4%, 85.7% and the control group was 71.4%, 60.0%, and there was significant difference compar- ing the treatment group with the control group, P〈0.05. After the treatment, each index of ECG improved signifi- cantly compared with the control group, and the CPR, BNP value in treatment group decreased significantly com- paring with the control group, P〈0.05. Heart rate, blood pressure, liver and kidney function and blood coagula- tion index in treatment group had no significant difference before and after treatment. Conclusion The fasudil hy- drochloride in treatment of unstable angina is effective and safe and worth of spreading and further studying.
出处 《中国心血管病研究》 CAS 2010年第5期334-336,共3页 Chinese Journal of Cardiovascular Research
关键词 盐酸法舒地尔 不稳定型心绞痛 Fasudil hydrochloride Unstable angina
  • 相关文献

参考文献4

二级参考文献34

  • 1李小鹰.阿司匹林在动脉硬化性心血管疾病中的临床应用:中国专家共识(2005)[J].中华心血管病杂志,2006,34(3):281-284. 被引量:194
  • 2[1]Manchanda SC.Treatment of stable angina with low dose diltiazem in combination with the metabolic agent trimetazidine.International Journal of Cardiology,2003,88:83-89.
  • 3[3]Marzilli M.Cardioprotective effects of trimetazidine:a review.Curr Med Res,2003,19:661-672.
  • 4[4]Ruiz-Meana M,Garcia-Dorado D,Julia M,et al.Pre-treatment with trimetazidine increase sarcolemmal mechanical resistance in reoxygenated myocytes.Cardiovasc Res,1996,32:587-592.
  • 5[5]Maupoil V,Rochette L,Tabard A,et al.Evaluation of free radical formation during low-flow ischemia and reperfusion isolated rat heart.Cardiovas Drugs Ther,1990,4(Suppl 4):S791-S795.
  • 6[6]Williams FM,Tanda K,Kus M,et al.Trimetazidine inhibits neutrophil accumulation after myocardial ischemia and reperfusion in rabbits.J Cardiovas pharmacol,1993,22:828-833.
  • 7[7]Noble MI,Belcher PR,Drake-Holland AJ.Limitation of infact size by trimetazidine European Multicenter Study Group.Br J Clin Pharmacol,1994,37:279-288.
  • 8[8]Ferrari R.Metabolic change in stunning and hibernation.Heart Metab,2000,10:3-10.
  • 9[9]Ferrari R.Metabolic treatment of myocardial ischaemia.European Heart J.1999,20:1144-1145.
  • 10[10]Cargnoni A,Pasini E,Ceconi C,et al.Insight into cytoprotection withmetabolic agents.European Heart J,1999,1:40-48.

共引文献6186

同被引文献48

  • 1张曼,屈晨,曾定尹.Rho/Rho激酶在压力负荷心力衰竭大鼠心肌组织的表达[J].中华心血管病杂志,2005,33(1):73-76. 被引量:52
  • 2张曼,佟浩,王文刚,张景轩,卜秀梅,曾定尹.法舒地尔对心力衰竭大鼠心室重塑干预与Rho GTPases活性的作用[J].中国新药与临床杂志,2007,26(9):671-674. 被引量:8
  • 3Leung T, Manser E, Tan L, et al. A novel serine/threonine ki- nas binding the ras-related RhoA GTPase which translocates the kinase toperipheral. J Biol Chem, 1995,270:29051-29054.
  • 4Shibuya M, Suzuki Y, Sugita K, et al. Dose escalation trial of a novel calcium antagonist, AT877, in patients with aneurysmal subarachnoid haemorrhage. Aeta Neurochir, 1990,107 : 1 l- 15.
  • 5Shibuya M, Suzuki Y, Sugita K, et al. Effect of AT877 on cere- bral vasospasm after aneurysmal subarachnoid hemorrhage. Re- suits of a prospective placebo-controlled double-blind trial. J Neurosurz, 1992,76 : 571-577.
  • 6Shimokawa H, Hiramori K, Iinuma H, et al. Antianginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina : a muhicenter study. J Cardiovasc Pharmacol, 2002,39 : 319-327.
  • 7Vicari RM, Smith WB, Chaitman B, et al. A randomized, dou- ble-blind, placebo-controlled, Phase 2 study: the efficacy of fa- sudil in patients with stable angina. Eur Heart J, 2004,25:138.
  • 8Shimokawa H. Long-term inhibition of Rho-kinaseinduces a re- gression of arterioscleroticcoronary lesions in a porcine model in vivo. Cardiovas Res,2001,51 : 169-177.
  • 9Higashi M. Long-term inhibition of Rho-kinasesuppresses an- giotensin lI-induced formation ofcoronar y vascular lesions an d car diachypertrophy in rats in vivo. Circulation, 2001,104 : 325.
  • 10Katsumata N, Shimokawa H, Seto M, et al. Enhanced myosinlight chain phosphorylations as a central mechanism for coronary artery spasm in a swine model with interleukin-1. Circulation, 1997,96 : 4357-4363.

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部